Human IGF-I/IGF-1 Antibody

R&D Systems, part of Bio-Techne | Catalog # MAB2912

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
MAB2912-100
MAB2912-SP
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Species Reactivity

Validated:

Human

Cited:

Human

Applications

Validated:

Neutralization

Cited:

Neutralization

Label

Unconjugated

Antibody Source

Monoclonal Rat IgG2A Clone # 997121

View all IGF-I/IGF-1 Antibodies »

Product Specifications

Immunogen

E. coli-derived recombinant human IGF-I/IGF-1
Gly49-Ala118
Accession # P05019

Specificity

Detects human IGF-I/IGF-1 in direct ELISAs.

Clonality

Monoclonal

Host

Rat

Isotype

IgG2A

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Scientific Data Images for Human IGF-I/IGF-1 Antibody

Cell Proliferation Induced by IGF-I/IGF-1 and Neutralization by Human IGF-I/IGF-1 Antibody.

Cell Proliferation Induced by IGF-I/IGF-1 and Neutralization by Human IGF-I/IGF-1 Antibody.

Recombinant Human IGF-I/IGF-1 (Catalog # 291-G1) stimulates proliferation in the MCF-7 human breast cancer cell line in a dose-dependent manner (orange line), as measured by Resazurin (Catalog # AR002). Proliferation elicited by Recombinant Human IGF-I/IGF-1 (10 ng/mL) is neutralized (green line) by increasing concentrations of Rat Anti-Human IGF-I/IGF-1 Monoclonal Antibody (Catalog # MAB2912). The ND50 is typically 0.1-0.8 µg/mL.

Applications for Human IGF-I/IGF-1 Antibody

Application
Recommended Usage

Neutralization

Measured by its ability to neutralize IGF-I/IGF-1-induced proliferation in the MCF‑7 human breast cancer cell line. Karey, K.P. et al. (1988) Cancer Research 48:4083. The Neutralization Dose (ND50) is typically 0.1-0.8 µg/mL in the presence of 10 ng/mL Recombinant Human IGF-I/IGF-1.

Formulation, Preparation, and Storage

Purification

Protein A or G purified from hybridoma culture supernatant

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Reconstitution Buffer Available:
Size / Price
Qty

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IGF-I/IGF-1

Insulin-like growth factor I, also known as somatomedin C, is the dominant effector of growth hormone and is structurally homologous to proinsulin. Human IGF-I is synthesized as two precursor isoforms with N- and alternate C-terminal propeptides (1). These isoforms are differentially expressed by various tissues (1). The 7.6 kDa mature IGF-I is identical between isoforms and is generated by proteolytic removal of the N- and C-terminal regions. Mature human IGF‑I shares 94% and 96% aa sequence identity with mouse and rat IGF-I, respectively (2), and exhibits cross-species activity. It shares 64% aa sequence identity with mature human
IGF‑II. Circulating IGF‑I is produced by hepatocytes, while local IGF-I is produced by many other tissues in which it has paracrine effects (1). IGF-I induces the proliferation, migration, and differentiation of a wide variety of cell types during development and postnatally (3). IGF-I regulates glucose and fatty acid metabolism, steroid hormone activity, and cartilage and bone metabolism (4-7). It plays an important role in muscle regeneration and tumor progression (1, 8). IGF-I binds IGF‑I R, IGF-II R, and the insulin receptor, although its effects are mediated primarily by IGF-I R (9). IGF-I association with IGF binding proteins increases its plasma half‑life and modulates its interactions with receptors (10).

References

  1. Philippou, A. et al. (2007) In Vivo 21:45.
  2. Sandberg-Nordqvist, A.C. et al. (1992) Brain Res. Mol. Brain Res. 12:275.
  3. Guvakova, M.A. (2007) Int. J. Biochem. Cell Biol. 39:890.
  4. Clemmons, D.R. (2006) Curr. Opin. Pharmacol. 6:620.
  5. Bluher, S. et al. (2005) Best Pract. Res. Clin. Endocrinol. Metab. 19:577.
  6. Garcia-Segura, L.M. et al. (2006) Neuroendocrinology 84:275.
  7. Malemud, C.J. (2007) Clin. Chim. Acta 375:10.
  8. Samani, A.A. et al. (2007) Endocrine Rev. 28:20.
  9. LeRoith, D. and S. Yakar (2007) Nat. Clin. Pract. Endocrinol. Metab. 3:302.
  10. Denley, A. et al. (2005) Cytokine Growth Factor Rev. 16:421.

Long Name

Insulin-like Growth Factor I/Insulin-like Growth Factor 1

Alternate Names

IGF-1, IGF1, IGFI, Somatomedin A, Somatomedin C

Entrez Gene IDs

3479 (Human); 16000 (Mouse); 24482 (Rat)

Gene Symbol

IGF1

UniProt

P05019

Additional IGF-I/IGF-1 Products

Product Documents for Human IGF-I/IGF-1 Antibody

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Human IGF-I/IGF-1 Antibody

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.